Objective: Older antiepileptic drugs (AEDs) are known to cause Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN). However, evidence for newer AED is sparse. We quantified risks of SJS/TEN in association with use of all AEDs in the United Kingdom. Methods: In a matched case-control study of 480 previously validated SJS/TEN cases (1995-2013) we used conditional logistic regression to calculate odds ratios (ORs) with 95% confidence intervals (CIs), and calculated absolute risks of SJS/TEN within separate cohorts of new users of 28 AEDs. We assessed causality between drugs and SJS/ TEN in each exposed case, using an adapted version of the algorithm of drug causality for epidermal necrolysis (ALDEN) score. Results: We observed a strong association between SJS/TEN and new use of carbamazepine (OR 92.57, 95% CI 19.89-∞), phenytoin (OR 49.96, 95% CI 10.13-∞), and lamotrigine (OR 26.90, 95% CI 4.88-∞), where causality, according to the ALDEN score, was very probable or probable for most exposed cases. Absolute risks for SJS/ TEN were highest for phenytoin (45.86 cases/100,000 exposed), lamotrigine (44.17 cases/100,000 exposed), and carbamazepine (20.38 cases/100,000 exposed). Despite increased ORs for valproate (40,941 exposed), gabapentin (116,037 exposed), pregabalin (59,967 exposed), and clobazam (4,300 exposed), ALDEN suggested no causal association. There were no observed cases of SJS/TEN among new users of levetiracetam (n = 96,77), clonazepam (n = 18,075), or topiramate (n = 11,307). Significance: The results of our study are consistent with those of previous studies of SJS/TEN, which found increased risks of SJS/TEN in new use of carbamazepine, phenytoin, and lamotrigine. Despite frequent use, no ALDEN-score confirmed cases were observed in new users of valproate, gabapentin, pregabalin, levetiracetam, topiramate, or clonazepam. KEY WORDS: Culprit drugs, Associations, Clinical practice research datalink.
30-50% mortality in TEN. 1, 2 In the absence of a generally accepted pharmacotherapy, early identification and discontinuation of the culprit drug is a key measure. [1] [2] [3] Two previous relatively large (n = 245 and 513 SJS/TEN cases) hospital-based case-control studies identified antiepileptic drugs (AEDs) as the alleged triggers of 25% of all hospitalized SJS/TEN cases. [4] [5] [6] Between 1989 and 1994, Roujeau et al. and Rzany et al. reported strongly increased odds ratios (ORs) for SJS/TEN in patients newly exposed (≤56 days) to carbamazepine, phenytoin, or phenobarbital in France, Germany, Italy, and Portugal. 5, 6 The more recently published EuroSCAR study conducted by Mockenhaupt et al. (a casecontrol study based in six European countries between 1997 and 2001) confirmed these findings and further observed a significantly increased risk of SJS/TEN after new exposure (≤56 days) to lamotrigine, a drug that became available between 1993 and 1994. 4 An association between SJS/TEN and valproate has been reported, but causality remains unconfirmed due to small sample size and frequent co-medication with other potentially causal drugs. [5] [6] [7] Case reports describe cases of SJS/TEN after exposure to gabapentin, clobazam, and zonisamide, [8] [9] [10] [11] but evidence on the potential association between SJS/TEN and AEDs other than carbamazepine, phenytoin, and phenobarbital is sparse, especially for drugs that have become available more recently.
We analyzed the relative and absolute risk of SJS/TEN in association with new use of AED within one of the largest validated SJS/TEN study populations using data from the UK-based Clinical Practice Research Datalink (CPRD). 12 
Patients and Methods

Data source
The CPRD is a large (13.3 million patient) anonymized primary care database that is representative of the United Kingdom population with regard to age and sex. Since 1987, participating general practitioners (GPs) have recorded information on patient demographics and characteristics, symptoms, diagnoses, laboratory test results, and referrals to consultants and secondary care. Drug prescriptions are issued electronically by the GP, and the CPRD thus holds a virtually complete outpatient drug prescription history. 13 The data in the CPRD have been repeatedly demonstrated to be of high quality, and have been used for numerous epidemiologic studies published in peer-reviewed journals.
14 This study was approved by the Independent Scientific Advisory Committee for MHRA database research (ISAC protocol 14_009R).
Study population
Case patients
We previously validated diagnoses of referred SJS/TEN cases recorded in the CPRD between 1995 and 2013, 12 where we established a population of 551 validated SJS/ TEN cases. The positive predictive value (PPV) for SJS/ TEN diagnoses in the CPRD was 0.87. The validation process is described in detail elsewhere. 12 In short, two specialized clinicians classified all potential referred cases of SJS/TEN into probable/possible or unlikely cases according to prespecified criteria using available clinical details in the CPRD patient record. We then compared our classification against a representative sample of patients for whom we had unequivocal diagnoses extracted from hospital discharge letters and hospital episode statistics data. Of the validated 551 cases, we included 480 patients who had ≥180 days of recorded active history in the CPRD prior to the index date. The index date was defined as the date of the first recorded SJS/TEN diagnosis (n = 238), or the date of the first recorded SJS/TEN-related symptom where available (e.g., sore throat symptom, rash, pain in eye) prior to the first recorded SJS/TEN diagnosis (n = 242).
Control patients
For each case, we randomly identified four control patients with no READ-code for SJS or TEN at any time, matched to cases on year of birth, sex, general practice, and years of recorded history prior to the index date. The index date for each control was the index date of the matched case. Control patients were required to have a recorded GP visit ≤30 days prior to or after the index date.
Exposure
We defined drug exposure as a first recorded prescription for an AED ≤84 days prior to the index date. We chose ≤84 days rather than ≤56 days (EuroSCAR study), 4 because the date of the first SJS/TEN record in the CPRD may not reflect the exact date of disease onset in every case (potential delay between patient presentation to emergency • We observed the highest risk of SJS/TEN of 45 cases/ 100,000 exposed patients within new users of phenytoin and lamotrigine followed by 20 cases/100,000 new users of carbamazepine
• We did not identify any cases of SJS/TEN in approximately equally high numbers of new users of levetiracetam, clonazepam, and topiramate. Few cases in new users of valproate, pregabalin, gabapentin, and clobazam were identified, but exposure to these drugs was likely not causally associated with SJS/TEN in any of the cases care and notification to the GP). We captured prescriptions for all AEDs that were on the market between 1995 and 2013 in the United Kingdom (Table S1 ).
Statistical analysis
Case-control
We conducted conditional logistic regression analyses using SAS statistical software version 9.4 (SAS Institute, Cary, NC, U.S.A.), and calculated ORs with 95% confidence intervals (CIs). Where there were no exposed cases/controls, we used exact methods to estimate the ORs and 95% CIs.
Because of the small number of exposed patients in each drug class, we did not perform multivariable adjustment, but presented concomitant new use of at least one other high-risk drug within 84 days before the index date (Table 1 for drugs).
Due to confidentiality regulations, we were not able to report the exact number of patients for categories that included fewer than five patients.
ALDEN
The algorithm of drug causality for epidermal necrolysis (ALDEN) score was developed in 2009 within the scope of the EuroSCAR study to assess drug causality for epidermal necrolysis 15 by systematically grading potential causality between drug exposure and adverse epidermal necrolysis (very probable, probable, possible, unlikely, or very unlikely) in affected patients. Because the score was developed for an inpatient setting, where more clinical information is available than in a study based on electronic databases, we assessed an adapted version of the ALDEN score for each case exposed to an AED ≤84 days prior to the index date, excluding information that is not available in the CPRD (Table S2) .
Cohort studies to quantify absolute risks
We established 28 individual cohorts of new users of 28 AED. Patients were eligible if they had ≥180 days of active history in the CPRD prior to the first prescription, and ≥84 days of completed follow-up after the recorded firsttime prescription in the database to allow for quantification of the absolute risk (cumulative incidence) in a population with complete follow-up. We excluded patients with any prior recorded diagnosis of SJS/TEN. We quantified absolute risks as the number of incident SJS/TEN diagnoses during follow-up, divided by the total number of new users of the same drug between 1995 and 2013. In a sensitivity analysis, we quantified absolute risks of SJS/TEN restricted to those exposed cases for which we assessed a very probable or probable ALDEN score for the respective drug.
Computer record review to assess reexposure to AED after SJS/TEN We reviewed patient records of all SJS/TEN cases after initiation of a high-risk AED (significantly associated in the case control analysis) within ≤84 days prior to disease onset, to anecdotally capture AED use after the SJS/TEN diagnosis.
Results
Our case-control study population included 480 SJS/TEN cases and 1,920 controls, of whom 51.7% were women. The mean age at the index date was 38.5 years (AE25.2). Of the 480 cases, 36 (7.5%) evidently started treatment with an AED within ≤84 days prior to the index date.
Case-control study Table 1 presents the association between new use of AED and incident SJS/TEN in the case-control analysis. We observed substantially increased ORs for carbamazepine (OR 92.27, 95% CI 16.83-∞), lamotrigine (OR 49.96, 95% CI 10.13-∞), phenytoin (OR 26.90, 95% CI 4.88-∞), and valproate (OR 10.51, 95% CI 1.25-∞). The ALDEN score was very probable or probable for 87.5% of cases newly exposed to carbamazepine, 88.9% for lamotrigine, and 100% for phenytoin, whereas causality for valproate was possible according to ALDEN for all newly exposed cases ( Fig. 1 ; ALDEN score for cases newly exposed to an AED ≤84 days prior to the index date), mainly because the timing of first exposure was >28 or <5 days before the index date. We observed increased ORs for the association between SJS/ TEN and gabapentin (OR 6.35, 95% CI 1.06-38.22), pregabalin (OR 4.00, 95% CI 0.21-∞), and clobazam (OR 4.00, 95% CI 0.21-∞; Table 1 ), although statistically nonsignificant for pregabalin and clobazam; ALDEN-based causality was very unlikely, unlikely, or possible for all cases newly exposed to either of these drugs (Fig. 1) . This likely noncausality was due mainly to concomitant new exposure to other high-risk drugs and to the timing of first-time exposure. We did not identify any cases of SJS/TEN in association with new use of phenobarbital (Table 1) , or with new use of primidone, ethosuximide, mesuximide, clonazepam, rufinamide, eslicarbazepine, oxcarbazepine, vigabatrin, tiagabine, sultiame, felbamate, topiramate, zonisamide, stiripentol, lacosamide, retigabine, perampanel, or beclamide (Table S3) .
Cohort study
Within 28 individual cohorts of new AED users, we quantified the highest absolute risk of SJS/TEN for phenytoin (cumulative incidence of 45.86 cases/100,000 new users), followed by 44.17 cases/100,000 new users of lamotrigine and 20.38 cases/100,000 new users of carbamazepine (all cases were very probable or probable according to ALDEN). We identified a total of 40,941 new users of valproate, 116,037 new users of gabapentin, 59,967 new users of pregabalin, and 4,300 new users of clobazam, which resulted in 0.27-4.89 cases/100,000 new users for valproate, gabapentin, and pregabalin. However, we only observed cases with very probable or probable (ALDEN scored) for phenytoin, lamotrigine and carbamazepine (Table 2) . We did not observe any cases of SJS/TEN among 18,075 new users of clonazepam, 11,307 new users of topiramate, or 9,677 new users of levetiracetam. We identified <5,000 new users and no cases of SJS/TEN in users of all other antiepileptics (Table S4 ).
Discussion
The results of this population-based observational study revealed a strong association between SJS/TEN and carbamazepine, lamotrigine, and phenytoin, with the highest absolute risk among new users of lamotrigine and phenytoin (both approximately 45 cases/100,000 new users), followed by carbamazepine (20 cases/100,000 new users). Despite similar numbers of new users of levetiracetam, topiramate, and clonazepam during the study period, we did not identify any cases of SJS/TEN among new users of these drugs. Despite increased ORs for valproate, gabapentin, pregabalin, and clobazam, cases did not meet the criteria for a causal association defined in ALDEN.
Two previous well-conducted hospital-based case-control studies reported increased risks of SJS/TEN in new users of aromatic AED (phenobarbital, phenytoin, and carbamazepine), [4] [5] [6] whereas a strong association between SJS/ TEN and new lamotrigine use, also an aromatic AED, was reported in only the more recent EuroSCAR study, given that the drug has only been available in the United Kingdom since 1993. 4 Our results confirm these substantially increased risks of SJS/TEN among users of carbamazepine, phenytoin, and lamotrigine with very probable or probable ALDEN scores. Mockenhaupt et al. calculated a higher absolute risk of SJS/TEN in association with new use of phenytoin (83 cases/100,000 new users), but slightly lower in association with lamotrigine (25 cases/100,000 new users) and carbamazepine (14 cases/100,000 new users) when compared to our study. 16 However, given the registry nature of the data source (Registry of Serious Cutaneous Reactions), they had to extrapolate the number of new users of AEDs in Germany based on the annual growth of daily doses dispensed, whereas in our study, new drug use and SJS/TEN cases were identified from the same base population. Exposure to phenobarbital, which was identified previously as one of the most common triggers of SJS/TEN, was low in our study (963 new users) due to decline in use since the 1980s. Previous evidence of a potential association between SJS/TEN and the nonaromatic AED valproate is equivocal. Roujeau et al. reported a strongly increased risk in 10 cases exposed to valproate, but did not assess concomitant drug use, 5 whereas the EuroSCAR study observed no significant risk for SJS/TEN based on two cases newly exposed to valproate. 4 We observed a tenfold increased risk of SJS/TEN in fewer than five cases newly exposed to valproate, all of whom scored only as possible causal cases in ALDEN, mainly due to the timing of the first recorded prescription (>56 days prior to the index date). All cases newly exposed to valproate had diagnoses of brain tumors recorded shortly before the index date, and were likely treated in secondary care, and thus may have received unrecorded drugs or procedures/therapies. 17 Among AEDs that have not been associated with SJS/TEN in previous analytic studies (gabapentin, clobazam, and zonisamide were associated with SJS/TEN in case reports), [8] [9] [10] [11] we observed increased ORs in new users of gabapentin, pregabalin, and clobazam, but ALDEN did not support causal associations. We observed <5 cases among a relatively high number of new users of drug gabapentin (116,037) and pregabalin (59,967), which were likely used at lower doses for the treatment of neuropathic pain in most cases. The ALDEN score for the 5 cases newly exposed to pregabalin and gabapentin further suggested no causality based on the timing of first exposure (>56 days prior to the index date) in 75%, and a concomitant lamotrigine prescription in the remaining 25%. All cases newly exposed to clobazam were concomitantly prescribed another high-risk AED, resulting in a "very unlikely" causality score in all cases (Table 1) .
There were no cases of SJS/TEN among new users of levetiracetam (9,677), topiramate (11, 307) , and clonazepam (18, 075) where the number of new users was similar to that of phenytoin (10,902) and lamotrigine (18, 112) . For all other AEDs, we identified <3,000 new users during the study period, and thus information on the risk of SJS/TEN was limited.
It remains to be explained why many AEDs are among the most frequently reported triggers of SJS/TEN. Carbamazepine, lamotrigine, phenobarbital, and phenytoin are all metabolized to arene oxide metabolites, which have been hypothesized to cause these adverse reactions. 18 Valproate, gabapentin, and pregabalin are neither aromatic nor are they metabolized to arene oxides, which may explain a likely noncausal association between SJS/TEN and these drugs.
Computer record review revealed that cases who were newly exposed to phenytoin prior to the index date and who did not die or leave the practice shortly after the SJS/TEN diagnosis (60% of exposed cases), were exclusively treated with valproate thereafter. Levetiracetam was used to substitute lamotrigine in SJS/TEN survivors (44.4% of all exposed cases), whereas valproate, phenytoin, and carbamazepine were each prescribed in 11% of exposed cases, of whom none were diagnosed with a second SJS/TEN during the available follow-up. Of all SJS/TEN cases newly exposed to carbamazepine, 50% did not have a recorded diagnosis for epilepsy or seizure prior to or after the index date, and were likely treated for neurologic disorders, such as trigeminal neuralgia. Of the 50% of carbamazepine users with an epilepsy diagnosis, 37.5% were treated with valproate after the SJS/TEN diagnosis, 25% with lamotrigine, and 12.5% with phenytoin. Neither of these cases had a second SJS/TEN recorded in their patient records after the index date. Thus our results suggest that a number of newer AEDs (levetiracetam, topiramate, clonazepam, and so on) are likely a safer alternative for antiepileptic therapy in patients with previous SJS/TEN, but further data are required to confirm these results. Although an aromatic AED was apparently substituted with a different aromatic AED in six cases, we cannot conclude from a retrospective database study that such an approach is safe.
Despite several strengths of this large population-based observational study, some limitations must be considered. First, despite extensive validation of our case population, some misclassification of SJS/TEN cases cannot be ruled out. Misclassification was less likely to occur in the two previous hospital-based case-control studies due to the available in-depth clinical information. 4, 5 In this database study, the well-known risk of SJS/TEN risk in association with AED may lead physician to overdiagnose SJS/TEN in AED users, which may have led to the inclusion of some falsepositive cases, and thus to slightly overestimated ORs. However, our results were similar to prior results, which provides confidence in the validity of our cases. 19 Second, the proportion of cases who were recently exposed to AEDs was lower in our study (7.5%) than in the two previous studies (both 25%), which may partially be explained by the use of different AEDs over time and by the decreasing use of phenobarbital. However, it is also possible that we missed some AED exposures, given that over the counter medication, in-hospital medication, and first-time prescriptions that are issued by specialists are not captured in the CPRD. In addition to underestimated ORs, this limitation could also have affected the assessment of concomitant use of other high-risk drugs for ALDEN in some cases. However, in a previous study based in the same study population, we observed increased risk of SJS/TEN only among patients with a diagnosis of epilepsy as well as a recent new prescription (≤84 days) of an AED, but not in epilepsy patients in the absence of such a prescription, suggesting that bias due to unobserved AED treatment is low in our study popyulation. 19 , Third, because ALDEN automatically grades causality higher for drugs with previous evidence for an association with SJS/TEN, the assessed likelihood for a causal association could potentially be underestimated for newer AEDs that have not previously been associated with SJS/TEN. However, the criterion of causal attribution (existing evidence on a potential association between a drug and SJS/TEN; Table S2 ) was not the decisive factor to classify probability of causality in most of the assessed cases. Finally, due to very low numbers of use of oxcarbazepine and eslicarbazepine in the United Kingdom, we were not able to assess these drugs. Especially oxcarbazepine is extensively used as monotherapy and add-on therapy for focal epilepsy in the United States and continental Europe, most particularly in cases of epilepsy of frontal and temporal origin. 20, 21 Both compounds have been associated with various cutaneous adverse skin reactions. 22 In summary, this population-based case-control study observed associations between SJS/TEN and new use of carbamazepine, lamotrigine, and phenytoin, with the highest absolute risk among users of phenytoin and lamotrigine. Despite a substantial number of users of levetiracetam, clonazepam, and topiramate, we did not identify any cases of SJS/TEN exposed to one of these drugs. This provides reassurance that these newer AEDs are not strongly associated with SJS/TEN.
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